Twist Bioscience Reports 24% Revenue Growth in Q1 FY25

Details

The company also saw an improvement in gross margin from 40.5% in Q1 FY24 to 48.3% in Q1 FY25. Twist expects its full-year revenue for fiscal 2025 to be between $372 million and $379 million, with a projected gross margin over 50% for the fourth quarter. The company further provided forward-looking guidance for the second quarter of fiscal 2025, anticipating total revenues of approximately $91 million to $93 million.

Items reported

Exhibits (1)

About Twist Bioscience Corporation

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.